Correlation of Troponin-I Level with Left Ventricular Ejection Fraction and In-hospital outcomes after First Attack

M H Khan1, M N Islam, G P Aditya

  • 1Dr Mahmood Hasan Khan, MD (Thesis) Student, Department of Cardiology, Mymensingh Medical College (MMC), Mymensingh, Bangladesh.

Insights

Elevated Troponin-I levels in patients experiencing their first Non-ST-segment Elevation Myocardial Infarction (NSTEMI) indicate poorer left ventricular (LV) function and worse in-hospital outcomes. Higher Troponin-I correlates with reduced LV ejection fraction, signaling increased cardiac damage.

Area of Science:

  • Cardiology
  • Biomarkers
  • Cardiac Function

Background:

  • Coronary heart disease (CHD) is a leading cause of premature death globally.
  • Acute coronary syndrome (ACS) diagnosis is critical for patient triage and management.
  • Troponin-I (cTnI) is a highly specific biomarker for myocardial infarction (MI).

Purpose of the Study:

  • To investigate the impact of elevated Troponin-I levels on left ventricular ejection fraction (LVEF).
  • To assess the relationship between Troponin-I levels and in-hospital outcomes in first-time Non-ST-segment Elevation Myocardial Infarction (NSTEMI) patients.

Main Methods:

  • Prospective analytical study including 130 first-attack NSTEMI patients.
  • Patients divided into groups based on LVEF (≥55% vs. <55%).
  • Correlation analysis between Troponin-I and LVEF using Pearson's correlation coefficient.

Main Results:

  • Patients with NSTEMI and lower LVEF (<55%) exhibited significantly higher mean Troponin-I levels (16.46±15.79 ng/ml) compared to those with preserved LVEF (5.53±7.43 ng/ml).
  • A statistically significant negative correlation (r=-0.5394, p=0.001) was observed between Troponin-I levels and LVEF.
  • Higher Troponin-I levels were associated with severe left ventricular systolic dysfunction and worse in-hospital outcomes.

Conclusions:

  • Elevated Troponin-I levels in first-attack NSTEMI patients are linked to reduced LV ejection fraction.
  • Higher Troponin-I levels predict poorer in-hospital outcomes in this patient cohort.
  • Troponin-I serves as a crucial indicator of myocardial damage and prognostic value in NSTEMI.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
939
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
298
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.1K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
468
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
711
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
355